EUVIMEDEUVIMED entdecken
Crossref

Central Retinal Artery Occlusion – Our Future Path to the Introduction of Intravenous Thrombolysis

Daria Sazanovych, Zuzana Schreiberová, Martina Sapieta, Klára Marešová, Daniel Šaňák, Petr Polidar, Marta Karhanová

Czech and Slovak Ophthalmology · 25.02.2026

DOI: 10.31348/2026/12 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Czech and Slovak Ophthalmology, online erschienen am 25.02.2026. Verfasst von Daria Sazanovych und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Retinal Artery Occlusion, Thrombolytic Therapy, Fibrinolytic Agents, Procaine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Retinal artery occlusion (RAO) is a vascular occlusive disorder and an acute condition in ophthalmological practice.

Purpose

To evaluate the effectiveness of treatment approaches used at our department in patients with RAO, particularly their impact on the resulting central visual acuity of the affected eye. Furthermore, to determine how many patients would meet the time window for intravenous thrombolysis (IVT) administration in the case of central retinal artery occlusion (CRAO). Material and Methods: This retrospective study included all the patients diagnosed with CRAO and BRAO (branch retinal artery occlusion) who received systemic treatment with intravenously administered vasodilators (Procaine®) at our department between 01/2020 and 08/2025. We monitored the time delay to examination, the type of healthcare facility upon first contact, the type of therapy, the duration of symptoms before the initiation of treatment, and risk factors. We evaluated the change in central visual acuity (CVA) before treatment and immediately after completion of therapy upon discharge from hospital.

Results

The study sample consisted of 73 eyes (51 with CRAO and 22 with BRAO). No significant improvement in CVA was observed after the administration of 0.2% procaine hydrochloride (Procaine®): the mean change in CVA before and after treatment was 0.045 in the BRAO group and 0.078 in the CRAO group. No significant association was found between CVA change and the number of administered Procaine doses. The average time from the onset of symptoms to examination at our ophthalmology clinic was 33.5 hours in the BRAO group and 28.4 hours in the CRAO group. The time window for potential IVT administration was met by 2 patients with BRAO (9%) and 14 patients with CRAO (27%).

Conclusion

We did not demonstrate any potential therapeutic effect of intravenously administered 0.2% procaine hydrochloride. Our results confirmed the need to establish a protocol for IVT administration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retinal Artery OcclusionThrombolytic TherapyFibrinolytic AgentsProcaineVasodilator AgentsHumansRetrospective StudiesFemaleMaleVisual AcuityAgedMiddle Aged

Stichwörter der Autor:innen

conventional treatment methodsintravenous thrombolysisprocaineretinal artery occlusionvasodilators

Substanzen

Fibrinolytic AgentsProcaineVasodilator Agents

Zitieren

APA

Sazanovych, D., Schreiberová, Z., Sapieta, M., Marešová, K., Šaňák, D., Polidar, P., & Karhanová, M. (2026). Central Retinal Artery Occlusion – Our Future Path to the Introduction of Intravenous Thrombolysis. Czech and Slovak Ophthalmology. https://doi.org/10.31348/2026/12

Vancouver

Sazanovych D, Schreiberová Z, Sapieta M, Marešová K, Šaňák D, Polidar P, et al. Central Retinal Artery Occlusion – Our Future Path to the Introduction of Intravenous Thrombolysis. Czech and Slovak Ophthalmology. 2026. doi:10.31348/2026/12

BibTeX
@article{Sazanovych2026,
  author = {Sazanovych, Daria and Schreiberová, Zuzana and Sapieta, Martina and Marešová, Klára and Šaňák, Daniel and Polidar, Petr and Karhanová, Marta},
  title = {Central Retinal Artery Occlusion – Our Future Path to the Introduction of Intravenous Thrombolysis},
  journal = {Czech and Slovak Ophthalmology},
  year = {2026},
  doi = {10.31348/2026/12}
}
Kostenlos starten →